Rein Therapeutics
RNTX
20 hedge funds and large institutions have $3.25M invested in Rein Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
104% more capital invested
Capital invested by funds: $1.59M → $3.25M (+$1.66M)
25% more funds holding
Funds holding: 16 → 20 (+4)
1.25% less ownership
Funds ownership: 23.03% → 21.78% (-1.3%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gagnon Securities
New York
|
+$74K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$32.3K |
| 3 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$30.8K |
| 4 |
Renaissance Technologies
New York
|
+$17.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30.4K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$29K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.45K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$1.36K |
RNTX Hedge Fund Activity: Q4 2023 in Review
20 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2023, worth a combined $3.25M — up 104% from $1.59M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RNTX positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Gagnon Securities, opening a new position worth an estimated $74K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $30.4K sold.
- 20 institutional investors held Rein Therapeutics (RNTX) as of Q4 2023, up from 16 in Q3 2023.
- Funds reported $3.25M of Rein Therapeutics stock for Q4 2023, up 104% quarter-over-quarter.
- 7 funds opened new Rein Therapeutics positions in Q4 2023 and 2 closed out, a net change of +5 holders.
- The largest Rein Therapeutics buyer in Q4 2023 was Gagnon Securities, an estimated $74K added.
- The largest Rein Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $30.4K sold.
Based on aggregated 13F filings for Q4 2023.